Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dustan Buckley

Internal Medicine Oklahoma City, OK Medical Doctor

NPI 1730171794 CMS profile 79064

9100 N May Ave, Oklahoma City, OK 73120

Open in the dashboard

General payments

$8,162

515 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dustan Buckley of Oklahoma City, OK is reported in the CMS Open Payments database as having received $8,162 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,693 91
2024 General $1,147 68
2023 General $1,066 65
2022 General $1,284 81
2021 General $1,174 79
2020 General $621 45
2019 General $1,175 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dustan Buckley
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dustan Buckley were reported at $1,693. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dustan Buckley Internal Medicine median Middle half National median
2019 $1,175 $159 $48–$570 $163
2020 $621 $119 $33–$402 $114
2021 $1,174 $135 $37–$521 $132
2022 $1,284 $141 $42–$496 $149
2023 $1,066 $149 $45–$519 $160
2024 $1,147 $154 $47–$537 $164
2025 $1,693 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $976 72 payments
  2. AbbVie, Inc. $975 59 payments
  3. Pfizer Inc. $685 49 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $684 41 payments
  5. Novo Nordisk Inc $613 44 payments
  6. AstraZeneca Pharmaceuticals LP $552 25 payments
  7. Lilly USA, LLC $464 35 payments
  8. Amgen Inc. $370 23 payments
  9. Sumitomo Pharma America, Inc. $275 13 payments
  10. Abbott Laboratories $265 14 payments
  11. Other $2,303 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,162 515 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $745 55 payments
  2. Ozempic $524 38 payments
  3. FARXIGA $478 20 payments
  4. RYBELSUS $448 32 payments
  5. LINZESS $427 25 payments
  6. GEMTESA $361 18 payments
  7. CREON $345 21 payments
  8. JARDIANCE $315 18 payments
  9. AIRSUPRA $266 7 payments
  10. SPIRIVA RESPIMAT $252 18 payments
  11. Other $7,274 478 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 185 drugs

Part D claims

11,581

Median for Internal Medicine: 777

Drug cost

$919,991

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 147 $163,997
Eliquis Apixaban Brand 108 $111,754
Mounjaro Tirzepatide Brand 63 $64,407
Farxiga Dapagliflozin Propanediol Brand 46 $50,700
Myrbetriq Mirabegron Brand 51 $50,049
Jardiance Empagliflozin Brand 43 $40,617
Xarelto Rivaroxaban Brand 21 $27,834
Trulicity Dulaglutide Brand 21 $27,363
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 31 $20,207
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $16,886

The 10 drugs with the highest cost, of 185 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$172,807

Of which drugs: $9,253

Medicare patients

593

Average age 76

Services billed

4,767

467 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 54%
Chronic kidney disease 33%
Depression 29%
Ischemic heart disease 28%
Diabetes 20%
Osteoporosis 18%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 72 73 $5,914

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $104
$104 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $83
$83 43 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $83
$83 46 —
RYBELSUS
  • Novo Nordisk Inc $66
$66 — —
Ozempic
  • Novo Nordisk Inc $66
$66 147 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record